Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
about
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseLong-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseThe effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseInjectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDAdvanced Chronic Obstructive Pulmonary Disease: Innovative and Integrated Management ApproachesComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisClinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic reviewPositioning new pharmacotherapies for COPDA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseTen years of tiotropium: clinical impact and patient perspectivesCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewA review of national guidelines for management of COPD in EuropeThe efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methodsCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analysesIncorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methodsSevere COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods.Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review.Intent-to-treat analysis in the presence of off-treatment or missing data.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updatePulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Is it possible to diagnose the therapeutic adherence of patients with COPD in clinical practice? A cohort study.A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.Influencing the decline of lung function in COPD: use of pharmacotherapy.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Update on the management of chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
P2860
Q24186411-C39D5ABE-4873-49A6-A5BD-9B5E5B1D2EC4Q24199130-CB813461-7BF3-4E3C-AF7F-034E1AB9B89BQ24200331-BA52AAFE-68EB-424A-B256-8BFDE913994DQ24200446-1332E0C0-CC16-47D9-913E-66A67F989EDBQ24202510-C89C3D9D-74FC-449C-9E25-7E9192210A49Q24234343-C8727479-AC97-4419-8922-A93E29CF23B7Q24235761-048911AE-EE27-497A-917E-FC2A4218EFDDQ24236699-D7E8A726-B41F-4C3A-9AF7-065A94935548Q24243515-260FBDF4-4232-48CD-8C4B-AF502196855FQ24243564-A360AEFD-B43B-48D0-BD07-4217E26FA735Q24243613-D73BE374-2E1B-433B-86CC-7708AD8AAA18Q26471530-30FA25C8-7F9E-4BE9-8D60-33730B75473CQ26776477-998C6F81-B710-4553-AAB4-AF2CD26D8A15Q26777611-71A69AF3-1B3A-4D6F-B417-84CC1699B182Q26782484-957E418C-EC1F-4C7D-8A60-0CC5E7927850Q26782630-586C8B5F-0DAE-48D0-836B-9D9C31548542Q26798659-09E75C96-E405-4439-BBFE-EA1E280E9B8BQ26801661-58626A04-CA12-4736-A049-CD7A7F50E7EFQ26823682-989C5317-89EF-4A0F-B044-40816ADF01EBQ27012625-351B4B74-8CA6-4FED-A5A1-3BE9E9533DF3Q27024384-90792769-66B4-4DA4-97D9-19F3FC8BBF2FQ27348844-0D536FE4-A6F0-483F-AD27-5123A820346CQ28068078-F75B62D6-BE14-410D-A5F6-1376AD861FA5Q28070274-360CC103-0538-419E-B31F-11F47F16B469Q28072014-499EC691-E56F-4597-AAC3-A29A403206FDQ28085193-AC0435D5-D71B-49A6-976A-C6315C3B5E58Q28391808-ABEC4072-0E57-444A-BD83-92B9E98DB977Q30419928-A8D74A0F-257E-4F22-8D9D-E89D4D2A514AQ30580634-34FF78BE-2257-4DEC-A945-FF1D0ECAD553Q31137121-08ECBCCC-DD2D-47ED-A346-6AD15897E258Q33491797-3D411FB8-0263-4E7D-A05B-23E59686CDC2Q33536518-C0131946-40F2-473D-A01B-FA1CAAADDD15Q33591899-3986F956-2229-4026-95A4-715926BA6388Q33711672-3580BA36-85ED-494C-B9FE-576FF3FE6CC4Q33801644-D7EB2415-C044-426A-B1C8-42B9D778000DQ33838209-7ABB00CB-244B-480C-B336-02B6271E2683Q33966001-BD1A7269-E5DE-4D29-A459-B00DE8A1DFD5Q34065276-81B99D33-FC8D-454B-BD59-95449AA3C8D9Q34196174-3C947174-FC6F-4859-8838-87CCC1C572C5Q34252132-39316870-B74A-4330-8FA7-B5D45AC56D41
P2860
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tiotropium in combination with ...... y disease: a randomized trial.
@en
Tiotropium in combination with ...... y disease: a randomized trial.
@nl
type
label
Tiotropium in combination with ...... y disease: a randomized trial.
@en
Tiotropium in combination with ...... y disease: a randomized trial.
@nl
prefLabel
Tiotropium in combination with ...... y disease: a randomized trial.
@en
Tiotropium in combination with ...... y disease: a randomized trial.
@nl
P2093
P1476
Tiotropium in combination with ...... y disease: a randomized trial.
@en
P2093
Andrew Hirsch
Andrew McIvor
Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium
Darcy Marciniuk
David McCormack
Dean Fergusson
Denis O'Donnell
Dominique Bleskie
François Maltais
George Fox
P304
P356
10.7326/0003-4819-146-8-200704170-00152
P407
P577
2007-02-19T00:00:00Z